Vaccine Safety Conference Company Profile

02:47 EST 20th February 2020 | BioPortfolio

News Articles [2485 Associated News Articles listed on BioPortfolio]

WHO’s rollout of malaria vaccine in Africa: can safety questions be answered after only 24 months?

Key messagesPhase III trials of the RTS,S malaria vaccine identified three safety concerns: higher risks of meningitis, cerebral malaria, and doubled female mortalityThese safety concerns are now... ...

Chlamydia vaccine passes safety trial

A first-of-its-kind experimental chlamydia vaccine trial has been found to be safe and able to provoke an immune response. The post Chlamydia vaccine passes safety trial appeared first on European Pha...

J&J, HHS join forces on coronavirus vaccine as Moderna makes progress

J&J will work under an existing partnership with the department to develop a vaccine against COVID-19, while Moderna sa

[Articles] Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial

The rVSVN4CT1-EBOVGP1 vaccine was well tolerated at all dose levels tested and was immunogenic despite a high degree of attenuation. The combined safety and immunogenicity profile of the rVSVN4CT1-EBO...

Complexity of Assessing the Benefit vs Risks of Vaccines

This Viewpoint uses experience with rotavirus vaccine–induced intussusception and dengue virus vaccine–induced shock syndrome to discuss issues of disease prevalence and severity underlying recomm...

News Headlines, PTV News: Mar 24, 2010

A look at today's forthcoming news stories: Pfizer and GSK in cut price vaccine deal for world's poorest; Merck Serono suspends trials of cancer vaccine after patient develops encephalitis, and Dynava...

Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101

Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety a...

Flu vaccination in pregnancy

A paper published in The BMJ this week (doi:10.1136/bmj.l4151) provides new data on the long term safety of influenza vaccine for children exposed to the vaccine in utero.1 The study by Walsh and... ...

Drugs and Medications [25 Associated Drugs and Medications listed on BioPortfolio]

Vivotif-b [rebel distributors corp]


Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Hepagam b [aptevo biotherapeutics llc]

These highlights do not include all the information needed to use HepaGam B safely and effectively. See full prescribing information for HepaGam B. HepaGam B [Hepatitis B Immune Globulin Intravenous (...

Tubersol [a-s medication solutions]

Tuberculin Purified Protein Derivative(Mantoux)TUBERSOL

Tubersol [a-s medication solutions]

Tuberculin Purified Protein Derivative(Mantoux)TUBERSOL

PubMed Articles [2323 Associated PubMed Articles listed on BioPortfolio]

Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain for the 2018/19 Season: Interim Analysis.

Influenza is an important cause of morbidity and mortality in Europe. Prevention by annual vaccination is most effective but with yearly vaccine reformulation to match circulating virus strains, vacci...

Profit considerations in vaccine safety-related events in China.

: China has made remarkable achievements in the field of immunization. However, several widespread vaccine safety-related events have recently received worldwide attention and reflect flaws in vaccine...

Enhanced Passive Safety Surveillance (EPSS) confirms an optimal safety profile of the use of MF59 -adjuvanted influenza vaccine in older adults: Results from three consecutive seasons.

In Europe, the enhanced safety surveillance (ESS) of seasonal influenza vaccines is mandatory, in order to detect any potential increase in reactogenicity when the vaccine composition is updated. The ...

A phase 1, randomized, observer blind, antigen and adjuvant dosage finding clinical trial to evaluate the safety and immunogenicity of an adjuvanted, trivalent subunit influenza vaccine in adults ≥ 65 years of age.

To assess the safety and immunogenicity of the MF59®-adjuvanted trivalent influenza vaccine (aTIV; Fluad®) compared with modified aTIV formulations.

Third Consensus Development Conference on the Safety of Intravenous Drug Delivery Systems-2018.

The Third Consensus Conference on the Safety of Intravenous Drug Delivery Systems was convened to evaluate the benefits and risks of available systems and assess ongoing threats to the safety of intra...

Clinical Trials [4091 Associated Clinical Trials listed on BioPortfolio]

Parent/Caregiver Conference Attendance Feasibility

This study will assess and evaluate conference attendance feasibility and will gather feedback about preferences and barriers to attendance at the American Society for Nutrition annual con...

Health Education for Physiotherapy in Soccer Players

INTRODUCTION. Health education based on interventions with new information and communication technologies. OBJECTIVE. To compare the effectiveness of an educational physiotherapy interven...

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

This study is aimed at assessing the safety and immunogenicity of different doses and formulations of a new Novartis Meningococcal B Recombinant Vaccine.

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV in...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Companies [1462 Associated Companies listed on BioPortfolio]

Vaccine Safety Conference

TruMed Systems, Inc.

TruMed Systems, a medical technology company, develops the innovative AccuVax® Vaccine Management System for healthcare professionals. AccuVax is a purpose-built vaccine manage...

Why We Vaccinate

Why We Vaccinate (WWV) is a not-for-profit coalition on a mission to advocate for pro-health legislation, improve immunization conversations between doctors and patients and respond to anti-vaccine m...

Geovax Labs

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines...

Coalition for Vaccine Safety

More Information about "Vaccine Safety Conference" on BioPortfolio

We have published hundreds of Vaccine Safety Conference news stories on BioPortfolio along with dozens of Vaccine Safety Conference Clinical Trials and PubMed Articles about Vaccine Safety Conference for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vaccine Safety Conference Companies in our database. You can also find out about relevant Vaccine Safety Conference Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record